Morning Overview on MSN
Seven years on, most lung cancer patients on one drug had no progression
More than half of patients with advanced ALK-positive lung cancer who started on lorlatinib seven years ago still have not ...
Adding tucatinib to standard first-line maintenance therapy in patients with HER2-positive metastatic breast cancer led to a clinically meaningful delay in disease progression, regardless of the ...
Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) delayed disease progression in patients with HER2-positive metastatic breast cancer, ...
Pfizer has rolled out detailed trial data suggesting Tukysa could be part of a new first-line treatment to delay the progression of HER2-positive breast cancer. The current standard of care for the ...
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced detailed results from the Phase 3 HER2CLIMB-05 trial of the tyrosine kinase inhibitor TUKYSA ® (tucatinib) as part of an ...
Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) delayed disease progression in patients with HER2-positive metastatic breast cancer, ...
Dual anti–human epidermal growth factor receptor 2 (HER2) therapy plus chemotherapy followed by maintenance treatment with HER2-targeted and endocrine therapies is standard first-line treatment for ...
In this segment, Dr. Gregory Vidal discusses the role of estrogen receptor antagonists in the treatment of ER-positive, HER2-negative metastatic breast cancer following progression on prior endocrine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results